Amulya Nidhi Shrivastava
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amulya Nidhi Shrivastava has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Triller
PSL Research University
11 shared publications - Marianne Renner
Sorbonne University - Institut du Fer à Moulin (IFM)
6 shared publications Luc Bousset
CEA Institut François Jacob (MIRcen) and CNRS Laboratory of Neurodegenerative Diseases (UMR9199) Fontenay‐aux‐Roses France
4 shared publications- Ronald Melki
Institut François Jacob (MIRCen) and CNRS, Fontenay-aux-Roses, France
4 shared publications - Virginie Redeker
Institut Francois Jacob (MIRCen), CEA, and Laboratory of Neurodegenerative Diseases, CNRS, Université Paris-Saclay, Fontenay-Aux-Roses, France
4 shared publications Laura Pieri
CEA Institut François Jacob (MIRcen) and CNRS Laboratory of Neurodegenerative Diseases (UMR9199) Fontenay‐aux‐Roses France
3 shared publications
Latest Publications
- Open Access
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (48)
Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies
Ligand-stimulated enzymatic release or cellular degradation of PrP may interfere with neurodegeneration-associated toxicity.
- 26 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (48)
Open AccessLigands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies
Ligand-stimulated enzymatic release or cellular degradation of PrP may interfere with neurodegeneration-associated toxicity.
- 1 June 2020
- Published by Elsevier in Neuropharmacology
- Vol. 169, 107461
Cell biology and dynamics of Neuronal Na+/K+-ATPase in health and diseases
- 1 June 2020
- Published by Elsevier in Neuropharmacology
- Vol. 169, 107461
Cell biology and dynamics of Neuronal Na+/K+-ATPase in health and diseases
- Open Access
- 1 March 2020
- Published by Elsevier in Biophysical Journal
- Vol. 118 (6) , 1301-1320
Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs
- 1 March 2020
- Published by Elsevier in Biophysical Journal
- Vol. 118 (6) , 1301-1320
Open AccessDifferential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs
- Open Access
- 10 January 2019
- Published by Springer Nature in The EMBO Journal
- Vol. 38 (3)
Clustering of Tau fibrils impairs the synaptic composition of α3‐Na+/K+‐ATPase and AMPA receptors
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 10 January 2019
- Published by Springer Nature in The EMBO Journal
- Vol. 38 (3)
Open AccessClustering of Tau fibrils impairs the synaptic composition of α3‐Na+/K+‐ATPase and AMPA receptors
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- Open Access
- 27 November 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (11) , e1006733
Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity
Prion infections cause inexorable, progressive neurological dysfunction and neurodegeneration. Expression of the cellular prion protein PrPC is required for toxicity, suggesting the existence of deleterious PrPC-dependent signaling cascades. Because group-I metabotropic glutamate receptors (mGluR1 and mGluR5) can form complexes with the cellular prion protein (PrPC), we investigated the impact of mGluR1 and mGluR5 inhibition on prion toxicity ex vivo and in vivo. We found that pharmacological inhibition of mGluR1 and mGluR5 antagonized dose-dependently the neurotoxicity triggered by prion infection and by prion-mimetic anti-PrPC antibodies in organotypic brain slices. Prion-mimetic antibodies increased mGluR5 clustering around dendritic spines, mimicking the toxicity of Aβ oligomers. Oral treatment with the mGluR5 inhibitor, MPEP, delayed the onset of motor deficits and moderately prolonged survival of prion-infected mice. Although group-I mGluR inhibition was not curative, these results suggest that it may alleviate the neurological dysfunctions induced by prion diseases. Prion diseases are a result of ordered accumulation of the misfolded conformer of cellular prion protein (PrPC), a GPI anchored protein expressed on the cell surface. Similar pathogenetic principles operate in several other neurodegenerative diseases. Currently no disease-modifying therapies exist and the situation is compounded by a dearth of validated therapeutic targets. In our present study, we have discovered that genetic ablation, or pharmacological inhibition, of group-I (i.e. activating) metabotropic glutamate receptors is beneficial against prion neurotoxicity in vitro and in vivo. Mice treated with these inhibitors exhibited impressive suppression of neurological signs and a delayed onset of the symptoms. These results further suggest that activation of these metabotropic glutamate receptors is a downstream event of prion replication and targeting these receptors could be a therapeutic option to alleviate the neurological symptoms, thereby ameliorating the quality of life in patients having prion infection.
- 27 November 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (11) , e1006733
Open AccessInhibition of group-I metabotropic glutamate receptors protects against prion toxicity
Prion infections cause inexorable, progressive neurological dysfunction and neurodegeneration. Expression of the cellular prion protein PrPC is required for toxicity, suggesting the existence of deleterious PrPC-dependent signaling cascades. Because group-I metabotropic glutamate receptors (mGluR1 and mGluR5) can form complexes with the cellular prion protein (PrPC), we investigated the impact of mGluR1 and mGluR5 inhibition on prion toxicity ex vivo and in vivo. We found that pharmacological inhibition of mGluR1 and mGluR5 antagonized dose-dependently the neurotoxicity triggered by prion infection and by prion-mimetic anti-PrPC antibodies in organotypic brain slices. Prion-mimetic antibodies increased mGluR5 clustering around dendritic spines, mimicking the toxicity of Aβ oligomers. Oral treatment with the mGluR5 inhibitor, MPEP, delayed the onset of motor deficits and moderately prolonged survival of prion-infected mice. Although group-I mGluR inhibition was not curative, these results suggest that it may alleviate the neurological dysfunctions induced by prion diseases. Prion diseases are a result of ordered accumulation of the misfolded conformer of cellular prion protein (PrPC), a GPI anchored protein expressed on the cell surface. Similar pathogenetic principles operate in several other neurodegenerative diseases. Currently no disease-modifying therapies exist and the situation is compounded by a dearth of validated therapeutic targets. In our present study, we have discovered that genetic ablation, or pharmacological inhibition, of group-I (i.e. activating) metabotropic glutamate receptors is beneficial against prion neurotoxicity in vitro and in vivo. Mice treated with these inhibitors exhibited impressive suppression of neurological signs and a delayed onset of the symptoms. These results further suggest that activation of these metabotropic glutamate receptors is a downstream event of prion replication and targeting these receptors could be a therapeutic option to alleviate the neurological symptoms, thereby ameliorating the quality of life in patients having prion infection.
- Open Access
- 1 June 2016
- Published by Elsevier in Data in Brief
- Vol. 7, 221-228
Data in support of the identification of neuronal and astrocyte proteins interacting with extracellularly applied oligomeric and fibrillar α-synuclein assemblies by mass spectrometry
- 1 June 2016
- Published by Elsevier in Data in Brief
- Vol. 7, 221-228
Open AccessData in support of the identification of neuronal and astrocyte proteins interacting with extracellularly applied oligomeric and fibrillar α-synuclein assemblies by mass spectrometry
- Open Access
- 1 December 2015
- Published by Elsevier in Cell Reports
- Vol. 13 (12) , 2768-2780
Bidirectional Control of Synaptic GABAAR Clustering by Glutamate and Calcium
- 1 December 2015
- Published by Elsevier in Cell Reports
- Vol. 13 (12) , 2768-2780
Open AccessBidirectional Control of Synaptic GABAAR Clustering by Glutamate and Calcium
- 31 August 2015
- Published by Springer Nature in The EMBO Journal
- Vol. 34 (19) , 2408-2423
α‐synuclein assemblies sequester neuronal α3‐Na+/K+‐ATPase and impair Na+ gradient
Extracellular α‐synuclein (α‐syn) assemblies can be up‐taken by neurons; however, their interaction with the plasma membrane and proteins has not been studied specifically. Here we demonstrate that α‐syn assemblies form clusters within the plasma membrane of neurons. Using a proteomic‐based approach, we identify the α3‐subunit of Na+/K+‐ATPase (NKA) as a cell surface partner of α‐syn assemblies. The interaction strength depended on the state of α‐syn, fibrils being the strongest, oligomers weak, and monomers none. Mutations within the neuron‐specific α3‐subunit are linked to rapid‐onset dystonia Parkinsonism (RDP) and alternating hemiplegia of childhood (AHC). We show that freely diffusing α3‐NKA are trapped within α‐syn clusters resulting in α3‐NKA redistribution and formation of larger nanoclusters. This creates regions within the plasma membrane with reduced local densities of α3‐NKA, thereby decreasing the efficiency of Na+ extrusion following stimulus. Thus, interactions of α3‐NKA with extracellular α‐syn assemblies reduce its pumping activity as its mutations in RDP/AHC.
- 31 August 2015
- Published by Springer Nature in The EMBO Journal
- Vol. 34 (19) , 2408-2423
α‐synuclein assemblies sequester neuronal α3‐Na+/K+‐ATPase and impair Na+ gradient
Extracellular α‐synuclein (α‐syn) assemblies can be up‐taken by neurons; however, their interaction with the plasma membrane and proteins has not been studied specifically. Here we demonstrate that α‐syn assemblies form clusters within the plasma membrane of neurons. Using a proteomic‐based approach, we identify the α3‐subunit of Na+/K+‐ATPase (NKA) as a cell surface partner of α‐syn assemblies. The interaction strength depended on the state of α‐syn, fibrils being the strongest, oligomers weak, and monomers none. Mutations within the neuron‐specific α3‐subunit are linked to rapid‐onset dystonia Parkinsonism (RDP) and alternating hemiplegia of childhood (AHC). We show that freely diffusing α3‐NKA are trapped within α‐syn clusters resulting in α3‐NKA redistribution and formation of larger nanoclusters. This creates regions within the plasma membrane with reduced local densities of α3‐NKA, thereby decreasing the efficiency of Na+ extrusion following stimulus. Thus, interactions of α3‐NKA with extracellular α‐syn assemblies reduce its pumping activity as its mutations in RDP/AHC.
β-amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors
β-Amyloid (Aβ) oligomers initiate synaptotoxicity following their interaction with the plasma membrane. Several proteins including metabotropic glutamate type 5 receptors (mGluR5s) contribute to this process. We observed an overexpression of mGluR5s in reactive astrocytes surrounding Aβ plaques in brain sections from an Alzheimer's disease mouse model. In a simplified cell culture system, using immunocytochemistry and single molecule imaging, we demonstrated a rapid binding of Aβ oligomers on the plasma membrane of astrocytes. The resulting aggregates of Aβ oligomers led to the diffusional trapping and clustering of mGluR5s. Further, Aβ oligomers induced an increase in ATP release following activation of astroglial mGluR5s by its agonist. ATP slowed mGluR5s diffusion in astrocytes as well as in neurons co-cultured with astrocytes. This effect, which is purinergic receptor-dependent, was not observed in pure neuronal cultures. Thus, Aβ oligomer- and mGluR5-dependent ATP release by astrocytes may contribute to the overall deleterious effect of mGluR5s in Alzheimer's disease. GLIA 2013;61:1673–1686
β-amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors
β-Amyloid (Aβ) oligomers initiate synaptotoxicity following their interaction with the plasma membrane. Several proteins including metabotropic glutamate type 5 receptors (mGluR5s) contribute to this process. We observed an overexpression of mGluR5s in reactive astrocytes surrounding Aβ plaques in brain sections from an Alzheimer's disease mouse model. In a simplified cell culture system, using immunocytochemistry and single molecule imaging, we demonstrated a rapid binding of Aβ oligomers on the plasma membrane of astrocytes. The resulting aggregates of Aβ oligomers led to the diffusional trapping and clustering of mGluR5s. Further, Aβ oligomers induced an increase in ATP release following activation of astroglial mGluR5s by its agonist. ATP slowed mGluR5s diffusion in astrocytes as well as in neurons co-cultured with astrocytes. This effect, which is purinergic receptor-dependent, was not observed in pure neuronal cultures. Thus, Aβ oligomer- and mGluR5-dependent ATP release by astrocytes may contribute to the overall deleterious effect of mGluR5s in Alzheimer's disease. GLIA 2013;61:1673–1686